Anti-Fas on Nonhematopoietic Tumors: Levels of Fas/APO-1 and bcl-2 Are Not Predictive of Biological Responsiveness

Cancer Research

Volumn 54, Issue 6, 1994, Pages 1580-1586

  Yonehara, Shin ^b   Berry, Karen ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JAPAN TOBACCO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; COLON CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ANTIGENS, CD95; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; APOPTOSIS; CELL DEATH; CELL DIVISION; HUMANS; NEOPLASMS, EXPERIMENTAL; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STIMULATION, CHEMICAL; TUMOR CELLS, CULTURED;

EID: 0028327190     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Wyllie, A.H., Kerr, J.F.R., and Currie, A.R. Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251-306, 1980.
2. McConkey, D.J., Aguilar-Santeelises, M., Hartzell, R, Ericksson, I., Mellstedt, H., Orrenius, S., and Jondal, M. Induction of DNA fragmentation in chronic B-lympho-cytic leukemia cells. J. Immunol., 146: 1072-1076, 1991.
3. Nunez, G., London, L., Hockenberry, D., Alexander, M., McKearn, J.R., and Korsmeyer, S. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoietic cell lines. J. Immunol., 144: 3602-3610, 1990.
4. Shi, Y., Glynn, J.M., Guilbert, L.J., Cotter, T.G., Bissonnette, R.P., and Green, D.R. Role for c-myc in activation-induced apoptotic cell death in T-cell hybridomas. Science (Washington DC), 257: 212-214, 1992.
5. Evan, G.I., WyUie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, M., Waters, C.M., Penn, L.Z., and Hancock, D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
6. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p. 3 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
7. Shaw, P., Bovey, B., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p. 3 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
8. Yonehara, S., Ishii, A., and Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 169: 1747-1756, 1989.
9. Trauth, B.C., Klas, C., Peters, A.M.J., Matzku, S., Moller, P., Falk, W., Debatin, K.M., and Krammer, P. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-305, 1989.
10. Watanabe-Fukunaga, R., Brannan, C., Itoh, N., Yonehara, S., Copeland, N.G., Jenkins, N.A., and Nagata, S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol., 148: 1274-1279, 1992.
11. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S.I., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233-243, 1991.
12. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B.C., Ponsting, I.H., and Krammer, P.H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem., 267: 10709-10715, 1992.
13. Itoh, N., and Nagata, S. A novel domain required for apoptosis: mutational analysis of human Fas antigen. J. Biol. Chem., 268: 10932-10937, 1993.
14. Suda, S., Takahashi, T., Goldstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a member of the tumor necrosis factor family. Cell, 75: 1169-1178, 1993.
15. Owen-Schaub, L.B., Yonehara, S., Crump, W.L., III, and Grimm, E.A. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol., 140: 197-205, 1992.
16. Miyawaki, T., Uehara, T., Nibu, R., Tsuji, T., Yachie, A., Yonehara, S., and Taniguchi, N. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol., 149: 3753-3758, 1992.
17. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., and Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (Lond.), 356: 314-317, 1992.
18. Adachi, M., Watanabe-Fukunaga, R., and Nagata, S. Aberrant transcription caused by the insertion ofan early transposable element in an intron of the Fas gene of Ipr mice. Proc. Natl. Acad. Sci. USA, 90: 1756-1760, 1993.
19. Wu, J., Zhou, T., He, J., and Mountz, J.D. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J. Exp. Med., 178: 461-468, 1993.
20. Chu, J.L., Drappa, J., Parnassa, A., and Elkon, K.B. The defect in Fas mRNA expression in MRL//pr mice is associated with insertion of the retrotransposon, ETn. J. Exp. Med., 178: 723-730, 1993.
21. Itoh, N., Tsujimoto, Y., and Nagata, S. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol., 151: 621-627, 1993.
22. Falk, M.H., Trauth, B.C., Debatin, K.M., Klas, C., Gregory, C.D., Rickinson, A.B., Calender, A., Lenoir, G.M., Ellwart, J.W., Krammer, P.H., and Bornkamm, G.W. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift toward a lymphoblastoid phenotype. Blood, 79: 3300-3306, 1992.
23. Mapara, M.Y., Bargou, R., Zugck, C., Dohner, H., Ustaoglu, F., Jonker, R.R., Krammer, P.H., and Dorken, B. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur. J. Immunol., 23: 702-708, 1993.
24. Kozlowski, J.M., Fidler, I.J., Campbell, D., Xu, Z.L., Kaighn, M.E., and Hart, I.R. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res., 44: 3522-3529, 1984.
25. Morikawa, K., Walker, S.M., Jessup, J.M., and Fidler, I.J. In vivo selection of highly metastatic cells from surgical specimens of different human colon carcinomas implanted into nude mice. Cancer Res., 48: 1943-1948, 1988.
26. Morikawa, K., Walker, S.M., Nakajima, M., Pathak, S., Jessup, J.M., and Fidler, I.J. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res., 48: 6863-6871, 1988.
27. Limin, L., Price, J.E., Fan, D., Zhang, R.D., Bucana, C.D., and Fidler, I.J. Correlation of growth capacity of human tumors in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J. Natl. Cancer Inst., 81: 1406-1412, 1989.
28. Mark, J., Westermark, B., Ponten, J., and Hugosson, R. Banding patterns in human glioma cell lines. Hereditas, 87: 243-260, 1977.
29. Aiello, A., Delia, D., Borrello, M.G., Biassoni, D., Giardini, R., Fontanella, E., Pezzella, F., Pulford, K., Pierotti, M., and Porta, G.D. Flow cytometric detection of the mitochondrial bcl-2 protein in normal and neoplastic human lymphoid cells. Cytometry, 13: 502-509, 1992.
30. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
31. Meyaard, L., Otto, S.A., Jonker, R.R., Mijnster, M.J., Keet, R.P.M., and Miedema, F. Programmed death of T-cells in HIV-1 infection. Science (Washington DC), 257: 217-219, 1992.
32. Leithauser, F., Dheln, J., Mechtersheimer, G., Koretz, K., Bruderlein, S., Henne, C., Schmidt, A., Debatin, K.M., Krammer, P.H., and Moller, P. Constitutive and induced expression of APO-1, a member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and malignant cells. Lab. Invest. 69: 415-429, 1993.
33. Hockenberry, D., Nunez, G., Milliman, C., Screiber, R.D., and Korsmeyer, S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334-336, 1990.
34. Chen-Levy, Z., Nourse, M., and Cleary, M.L. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral membrane protein expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol. Cell. Biol., 9: 701-710, 1989.
35. Nunez, G., Seto, M., Seremetis, S., Ferrero, D., Grignani, F., Korsmeyer, S.J., and Dalla-Favera, R. Growth- and tumor-promoting effects of deregulated bcl-2 in human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 86: 4589-4593, 1989.
36. Sentman, C.L., Shutter, J.R., Hockenberry, D., Kanagawa, O., and Korsmeyer, S.J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67: 879-888, 1991.
37. Strasser, A., Harris, A.W., and Cory, S. bcl-2 transgene inhibits T-cell death and perturbs thymic self-censorship. Cell, 67: 889-899, 1991.
38. Miyashita, T., and Reed, J.C. bcl-2 transfer increases the relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52: 5407-5411, 1992.
39. Hashimoto, S., Ishii, A., and Yonehara, S. The Elb oncogene of adenovirus confers cellular resistance to cytotoxicity of tumor necrosis factor and monoclonal anti-Fas antibody. Int. Immunol., 3: 343-351, 1991.
40. Oltvai, Z.N., Milliman, C.L., and Korsmeyer, S.J. bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
41. Boise, L.H., Gonzalez-Garcia, M., Postema, C.E., Ding, L., Lindsten, T., Turka, L.A., Mao, X., Nunez, G., and Thompson, C.B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-608, 1993.
42. Rouvier, E., Luciani, M.F., and Goldstein, P. Fas involvement in Ca2+-independent T-cell-mediated cytotoxicity. J. Exp. Med., 177: 195-200, 1993.